Novel therapy for the treatment of hyperphosphataemia

Specialty pharmaceutical company focused on the development and commercialisation of mineral-derived, late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need.


Lead product PT20

PT20 is a novel oral ferrihydrite based therapy for the treatment of hyperphosphataemia associated with end-stage renal disease. Hyperphosphataemia is a life-threatening complication of chronic kidney disease (CKD), the incidence of which is itself increasing across the world as obesity levels rapidly rise.

  

Ongoing development

PT20 acts as a ‘phosphate sponge’ and data from early studies suggest it exhibits higher binding capacity than market leading phosphate binders due to changes in the ferrihydrite crystal structure following a proprietary manufacturing process.

In addition, the low systemic absorption and the well-tolerated nature of ferrihydrite indicate that a very good side effect profile should be expected.


www.shieldtherapeutics.com